Reuters: Regulatory News: Raptor's rare disease drug recommended in Europe

Changes are afoot at Blogtrottr! By popular request, we're bringing in paid plans with some cool new features (and more on the way). You can read all about it in our blog post.

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Raptor's rare disease drug recommended in Europe Jun 28th 2013, 11:40 LONDON, June 28 | Fri Jun 28, 2013 7:40am EDT LONDON, June 28 (Reuters) - European regulators have recommended approval of a drug from Raptor Pharmaceutical to treat a rare genetic disorder that can cause irreversible tissue damage, organ failure and premature death. Friday's green light for Procysbi from the European Medicines Agency (EMA) follows U.S. approval of the drug in April. The medicine is designed to treat nephropathic cystinosis, the most common form of a disease known as cystinosis, in which toxic levels of cystine, a naturally occurring amino acid, build up in the body's cells and organs. The EMA also issued approvals for GlaxoSmithKline's Tafinlar for metastatic melanoma and Sanofi's multiple sclerosis medicine Lemtrada. It also revised its previous opinion not to give Sanofi's multiple sclerosis pill Aubagio 'new active substance' status in what it said was one of the busiest meetings of the CHMP in 2013 so far. Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions